Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. 2006

Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Akihiko Ito, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
Division of Surgical Pathology, Department of Biomedical Informatics, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.

Overexpression of the enhancer of zeste homolog 2 (EZH2) protein, a known repressor of gene transcription, has been reported to be associated with biological malignancy of prostate cancer and several other cancers. The purpose of this study was to examine the expression of EZH2 and analyze its relationship with the clinicopathological features of human gastric cancers. Expression levels of EZH2 mRNA and protein were examined in 13 gastric cancer cell lines and in 83 surgically removed human gastric cancer tissues. Immunohistochemical analysis of the 83 tissue samples and corresponding non-cancerous gastric mucosa showed that EZH2 was more highly expressed in the cancerous than in the non-cancerous tissues, and the expression levels of EZH2 were highly correlated with tumor size, depth of invasion, vessel invasion, lymph node metastasis and clinical stages. Univariate analysis of survival rate calculated by the Kaplan-Meier method revealed that gastric cancer patients with high-level EZH2 expression had poorer prognosis than those expressing no or low levels of EZH2 (P = 0.0271). These findings suggest that overexpression of EZH2 may contribute to the progression and oncogenesis of human gastric cancers, and thus immunohistochemical study of EZH2 expression may serve as a new biomarker for predicting the prognosis of gastric cancers.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071221 Enhancer of Zeste Homolog 2 Protein A histone-lysine N-methyltransferase and catalytic subunit of Polycomb Repressive Complex 2. It methylates LYSINE 9 (H3K9me) and LYSINE 27 (H3K27me) of HISTONE H3, leading to transcriptional repression of the affected target gene. EZH2 also methylates non-histone proteins such as GATA4 TRANSCRIPTION FACTOR and the nuclear receptor RORA. It regulates CIRCADIAN CLOCKS via histone methylation of circadian protein gene PROMOTER REGIONS, and its repressive activity is also important for the identity and differentiation of EMBRYONIC STEM CELLS. Enhancer of Zeste Homolog 2,Histone-Lysine N-Methyltransferase EZH2,Lysine N-Methyltransferase-6,EZH2, Histone-Lysine N-Methyltransferase,Histone Lysine N Methyltransferase EZH2,Lysine N Methyltransferase 6
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated

Related Publications

Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Akihiko Ito, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
March 2010, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Akihiko Ito, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
June 2016, Urologic oncology,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Akihiko Ito, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
January 2022, Frontiers in neuroscience,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Akihiko Ito, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
September 2011, The American journal of the medical sciences,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Akihiko Ito, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
May 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Akihiko Ito, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
November 2015, Virchows Archiv : an international journal of pathology,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Akihiko Ito, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
January 2018, Journal of chemical information and modeling,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Akihiko Ito, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
January 2020, Technology in cancer research & treatment,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Akihiko Ito, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
July 2018, Leukemia & lymphoma,
Yasuko Matsukawa, and Shuho Semba, and Hirotaka Kato, and Akihiko Ito, and Kazuyoshi Yanagihara, and Hiroshi Yokozaki
November 2019, Medicine,
Copied contents to your clipboard!